TG Therapeutics, Inc. (FRA:NKB2)

TG Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 9, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	3,578	4,173	2,186	1,482	2,188	5,479
Market Cap Growth	-19.64%	90.90%	47.46%	-32.24%	-60.07%	464.68%
Enterprise Value	3,684	4,088	2,078	1,395	1,899	5,306
Last Close Price	25.86	30.94	15.86	10.38	16.85	41.70
PE Ratio	9.38	184.75	190.66	-	-	-
PS Ratio	7.89	13.13	10.34	568.84	371.96	44096.70
PB Ratio	6.91	19.43	15.05	27.04	10.49	12.91
P/TBV Ratio	6.91	19.43	15.05	27.41	10.53	12.93
EV/Sales Ratio	8.06	12.87	9.83	535.24	322.82	42698.06
EV/EBITDA Ratio	40.86	100.79	110.20	-	-	-
EV/EBIT Ratio	41.69	100.95	111.33	-	-	-
Debt / Equity Ratio	0.42	1.14	0.69	1.42	0.34	0.08
Debt / EBITDA Ratio	2.43	5.74	4.82	-	-	-
Asset Turnover	0.66	0.73	0.89	0.01	0.01	0
Inventory Turnover	0.67	0.51	-	-	-	-
Quick Ratio	2.53	4.85	5.00	3.04	4.84	6.92
Current Ratio	3.83	6.25	5.92	3.16	5.06	6.99
Return on Equity (ROE)	111.96%	12.21%	11.57%	-151.36%	-92.03%	-100.14%
Return on Assets (ROA)	7.98%	5.78%	4.93%	-47.61%	-42.87%	-43.36%
Return on Capital (ROIC)	9.82%	7.00%	6.24%	-59.52%	-49.04%	-53.28%
Return on Capital Employed (ROCE)	11.80%	8.60%	7.50%	-155.50%	-109.70%	-50.80%
Earnings Yield	10.66%	0.54%	0.52%	-14.13%	-13.99%	-4.17%
FCF Yield	-1.67%	-0.94%	-1.30%	-11.12%	-11.90%	-3.21%
Buyback Yield / Dilution	-11.64%	-7.96%	-9.67%	-2.41%	-14.64%	-30.51%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.